Synonyms: SB-683699 | SB683699
Compound class:
Synthetic organic
Comment: Firategrast (SB-683699) is an orally bioavailable, short-acting small molecule α4-integrin antagonist. It was designed to reduce α4β1/α4β7 integrin-mediated trafficking of lymphocytes into the central nervous system (CNS). Anti-α4-integrin natalizumab is currently approved to treat MS, but its long half-life is problematic, and it has to be administered by infusion. This short acting small molecule was developed as an alternative to antibody therapy.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
INN number | INN |
8755 | firategrast |
Synonyms ![]() |
SB-683699 | SB683699 |
Database Links ![]() |
|
CAS Registry No. | 402567-16-2 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL2104967 |
DrugBank Ligand | DB12732 |
GtoPdb PubChem SID | 440816854 |
PubChem CID | 9935681 |
Search Google for chemical match using the InChIKey | YLFZHHDVRSYTKT-NRFANRHFSA-N |
Search Google for chemicals with the same backbone | YLFZHHDVRSYTKT |
Search PubMed clinical trials | firategrast |
Search PubMed titles | firategrast |
Search PubMed titles/abstracts | firategrast |
UniChem Compound Search for chemical match using the InChIKey | YLFZHHDVRSYTKT-NRFANRHFSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | YLFZHHDVRSYTKT-NRFANRHFSA-N |